Loading clinical trials...
Loading clinical trials...
Czech Pharmaco-epidemiological Real World Data Study Focused on Effectiveness of Different Disease Modifying Drugs
Conditions
Interventions
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
Locations
1
Czechia
IMPULS Endowment Fund
Prague, Czechia
Start Date
January 1, 2019
Primary Completion Date
December 31, 2021
Completion Date
December 31, 2021
Last Updated
March 9, 2023
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07376772
NCT07426991
Lead Sponsor
IMPULS Endowment Fund
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions